PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

💟 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. MEENAL					
AGE/ GENDER	: 35 YRS/FEMALE	PATIENT ID	: 156	6129		
COLLECTED BY	:	REG. NO./LAB NO.	: 122	2407310004		
REFERRED BY	:	REGISTRATION DA	ATE : 31/J	lul/2024 09:00 AM		
BARCODE NO.	: 12503906	COLLECTION DATE	E : 31/J	lul/2024 09:58AM		
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 31/J	ul/2024 01:13PM		
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA					
Test Name	Val	ue Unit	t	Biological Reference interval		
		HAEMATOLOGY				
		AEMOGLOBIN (HB)				
HAEMOGLOBIN (HB)		8 gm/	/dL	12.0 - 16.0		
by CALORIMETRIC						
<u>INTERPRETATION:-</u> Hemoglobin is the pr	otein molecule in red blood cells that carri	es oxvaen from the lunas to	the bodys tiss	ues and returns carbon dioxide from t		
tissues back to the lu	ings.		,			
A low hemoglobin lev	vel is referred to as ANEMIA or low red bloc HAFMOGLOBIN):	od count.				
1) Loss of blood (trau	umatic injury, surgery, bleeding, colon can	cer or stomach ulcer)				
	ncy (iron, vitamin B12, folate) plems (replacement of bone marrow by can	cor)				
4) Suppression by rea	d blood cell synthesis by chemotherapy dru	uqs				
5) Kidney failure						
6) Abnormal hemog	obin structure (sickle cell anemia or thalas REASED HAEMOGLOBIN):	ssemia).				
	lititudes (Physiological)					
2) Smoking (Seconda	ry Polycythemia)					
	uces a falsely rise in hemoglobin due to inc	creased haemoconcentration	n			
 Advanced lung dise Certain tumors 	ease (for example, emphysema)					
6) A disorder of the b	oone marrow known as polycythemia rubra					
1) Alaura af tha almum	anythropostin (Engrap) by athlatas for blag	ad dan han numpagan (in an and	ing the emount	of an una a challada ta tha baalu bu		

7) Abuse of the drug erythropoetin (Epogen) by athletes for blood doping purposes (increasing the amount of oxygen available to the body by chemically raising the production of red blood cells).

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600, REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. MEENAL				
AGE/ GENDER	: 35 YRS/FEMALE	PATI	ENT ID	: 1566129	
COLLECTED BY	:	REG.	NO./LAB NO.	: 122407310004	
REFERRED BY	: : 12503906 : P.K.R JAIN HEALTHCARE INSTITUTE		STRATION DATE	: 31/Jul/2024 09:00 AM : 31/Jul/2024 09:58AM : 31/Jul/2024 01:13PM	
BARCODE NO.			COLLECTION DATE		
CLIENT CODE.			DRTING DATE		
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD	, AMBALA CITY - HARYAN	A		
Test Name		Value	Unit	Biological Reference interval	
	CL	INICAL CHEMISTRY	/BIOCHEMISTR	Y	
		LIPID PROFILE	: BASIC		
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP		153.71	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.	
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		87.19	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0	
HDL CHOLESTEROL (E by SELECTIVE INHIBITION		50.08	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0	
LDL CHOLESTEROL: Si by CALCULATED, SPEC		86.19	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0	
NON HDL CHOLESTEROL: SERUM by calculated, spectrophotometry		103.63	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189. HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0	
VLDL CHOLESTEROL: by CALCULATED, SPEC		17.44	mg/dL	0.00 - 45.00	
TOTAL LIPIDS: SERUN	1	394.61	mg/dL	350.00 - 700.00	
by CALCULATED, SPECTROPHOTOMETRY CHOLESTEROL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY		3.07	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0	
LDL/HDL RATIO: SERI	IM	1.72	RATIO	LOW RISK: 0.50 - 3.0	

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)**



P K R JAIN HEALTHCARE INSTITUTE

NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

RATIO

A PIONEER DIAGNOSTIC CENTRE

MODERATE RISK: 3.10 - 6.0

HIGH RISK: > 6.0

3.00 - 5.00

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. MEENAL			
AGE/ GENDER	: 35 YRS/FEMALE	PATIENT ID	: 1566129	
COLLECTED BY	:	REG. NO./LAB NO.	: 122407310004	
REFERRED BY	:	REGISTRATION DATE	: 31/Jul/2024 09:00 AM	
BARCODE NO.	: 12503906	COLLECTION DATE	: 31/Jul/2024 09:58AM	
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 31/Jul/2024 01:13PM	
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA			
Test Name	Value	Unit	Biological Reference interval	

by CALCULATED, SPECTROPHOTOMETRY

TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY **INTERPRETATION:**

1.Measurements in the same patient can show physiological& analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the

1.74^L

age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

* End Of Report **



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)**

